Despite promising preclinical data and safety in humans, the first clinical inhibitor of TREM-1 (peptide LR12 or nangibotide) failed to reach significance for the primary endpoint in ASTONISH phase IIb sepsis trial (7, 8). This evidence concerns the gene TREM1 and Sepsis.